Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 12/09 10:00:00 pm
76.67 USD   -0.71%
12/02 VERTEX PHARMACE : VRTX) Files An 8-K Departure of Directors or Certa..
11/29 NASDAQ 100 MOVE : Bmrn, nflx
11/11 NASDAQ 100 MOVE : Alxn, nvda
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/02/2016 | 02:55pm CET

VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On December 2, 2016, Vertex announced several changes to
our>senior leadership team that are designed to provide
long-term stability and leadership through the continued growth
and expansion of Vertexs business. Principal among these changes
is the extension of our CEOs contract. The changes also include
the creation of new roles that reflect the advancement and
increased complexity of our business.
(c) Appointment of Certain Officers
Effective January 1, 2017, we have appointed Ian F. Smith our EVP
Chief Operating Officer and Chief Financial Officer and Michael
Parini our EVP Chief Legal and Administrative Officer. Additional
information regarding Mr. Smith and Mr. Parini is included in
Item 1 of our Annual Report on Form 10-K, filed with the SEC on
February 16, 2016 and incorporated herein by reference.
(e) Compensatory Arrangements with Named Executive Officer
On November 30, 2016, we amended and restated our employment
agreement with our Chairman, President and Chief Executive
Officer, Dr. Jeffrey M. Leiden. The amended and restated
agreement replaces our employment agreement with Dr. Leiden,
which was originally entered into in December 2011 and previously
amended in December 2014. to the amended and restated employment
agreement:
The term of Dr. Leidens employment agreement (which was
previously scheduled to expire on December 31, 2017) was
extended through March 31, 2020.
Dr. Leidens annual base salary, target bonus and equity
compensation program remained the same.
His benefits upon a termination by us without cause or by
Dr. Leiden for good reason were adjusted as follows:
o
Dr. Leidens cash severance benefit was reduced from 200% of
the sum of his base salary and target bonus to 50% of the
sum of his base salary and target bonus; and
o
For stock options granted starting in 2014 and restricted
stock awards/restricted stock awards granted starting in
2015, in lieu of the 18 months of acceleration/continued
vesting he would receive partial vesting of such awards in
a percentage based on his years of service as an employee
and/or non-employee director. This percentage would
initially be 70% and would increase by 10% for each full
year of service to the company. In addition, his stock
options granted starting in 2014, would each remain
outstanding for its original ten-year term.
> The other material terms of Dr. Leidens employment agreement
were not amended.
The foregoing summary of the amended and restated agreement is
qualified in its entirety by the full text of the amended and
restated agreement, which is filed as Exhibit 10.1 hereto and
incorporated herein by reference.
In connection with the foregoing appointments, Mr. Smiths base
salary was increased to $850,000 and his target bonus was
increased to 75% of his annual base salary and Mr. Parinis base
salary was increased to $675,000.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description of Document
>
10.1
Amended and Restated Employment Agreement, dated November
30, 2016, by and between Vertex Pharmaceuticals
Incorporated
and Jeffrey M. Leiden, M.D., Ph.D

About VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210. VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Recent Trading Information
VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) closed its last trading session 00.00 at 77.82 with 2,662,560 shares trading hands.

The post VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers appeared first on Market Exclusive.

© Market Exclusive 2016, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
12/02 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Departure of Directors..
12/02 VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers (for..
11/29 NASDAQ 100 MOVERS : Bmrn, nflx
11/17 VERTEX PHARMACEUTICALS INCORPORATED : Positive Phase 3 Study of ORKAMBI® in Chil..
11/14 VERTEX PHARMACEUTICALS INCORPORATED : Assigned Patent
11/11 NASDAQ 100 MOVERS : Alxn, nvda
11/10 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the Credit Suisse Healthcare..
11/09 VERTEX PHARMACEUTICALS INCORPORATED : (VRTX) Pops 11.92% for November 09
11/07 VERTEX PHARMACEUTICALS INCORPORATED : Positive Phase 3 Study of ORKAMBI® in Chil..
11/03 VERTEX PHARMACEUTICALS INCORPORATED : Announces Planned Initiation of Phase 2 St..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/09 They're Definitely High On Something
12/02 Vertex promotes two execs
11/30 Cystic Fibrosis Spotlight Turns To Galapagos
11/29 Barclays softens views on five biopharma firms
11/29 Galapagos launches early-stage study of corrector drug for cystic fibrosis, e..
Advertisement
Financials ($)
Sales 2016 1 693 M
EBIT 2016 182 M
Net income 2016 -134 M
Finance 2016 185 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 76,14
EV / Sales 2016 11,1x
EV / Sales 2017 8,45x
Capitalization 19 017 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 102 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith Chief Financial Officer & Executive Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-39.07%19 017
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
CELGENE CORPORATION-5.25%87 962
REGENERON PHARMACEUTIC..-31.32%39 322
ACTELION LTD50.21%22 204
More Results